Literature DB >> 33500176

Dynamics of Cortical Degeneration Over a Decade in Huntington's Disease.

Eileanoir B Johnson1, Gabriel Ziegler2, William Penny3, Geraint Rees4, Sarah J Tabrizi5, Rachael I Scahill6, Sarah Gregory6.   

Abstract

BACKGROUND: Characterizing changing brain structure in neurodegeneration is fundamental to understanding long-term effects of pathology and ultimately providing therapeutic targets. It is well established that Huntington's disease (HD) gene carriers undergo progressive brain changes during the course of disease, yet the long-term trajectory of cortical atrophy is not well defined. Given that genetic therapies currently tested in HD are primarily expected to target the cortex, understanding atrophy across this region is essential.
METHODS: Capitalizing on a unique longitudinal dataset with a minimum of 3 and maximum of 7 brain scans from 49 HD gene carriers and 49 age-matched control subjects, we implemented a novel dynamical systems approach to infer patterns of regional neurodegeneration over 10 years. We use Bayesian hierarchical modeling to map participant- and group-level trajectories of atrophy spatially and temporally, additionally relating atrophy to the genetic marker of HD (CAG-repeat length) and motor and cognitive symptoms.
RESULTS: We show, for the first time, that neurodegenerative changes exhibit complex temporal dynamics with substantial regional variation around the point of clinical diagnosis. Although widespread group differences were seen across the cortex, the occipital and parietal regions undergo the greatest rate of cortical atrophy. We have established links between atrophy and genetic markers of HD while demonstrating that specific cortical changes predict decline in motor and cognitive performance.
CONCLUSIONS: HD gene carriers display regional variability in the spatial pattern of cortical atrophy, which relates to genetic factors and motor and cognitive symptoms. Our findings indicate a complex pattern of neuronal loss, which enables greater characterization of HD progression.
Copyright © 2020 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atrophy; Cortex; Huntington’s disease; Imaging; Longitudinal; Subcortex

Mesh:

Year:  2020        PMID: 33500176      PMCID: PMC7986936          DOI: 10.1016/j.biopsych.2020.11.009

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  50 in total

1.  Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity.

Authors:  H Diana Rosas; David H Salat; Stephanie Y Lee; Alexandra K Zaleta; Vasanth Pappu; Bruce Fischl; Doug Greve; Nathanael Hevelone; Steven M Hersch
Journal:  Brain       Date:  2008-03-12       Impact factor: 13.501

2.  Longitudinal atrophy characterization of cortical and subcortical gray matter in Huntington's disease patients.

Authors:  Gabriel Ramirez-Garcia; Víctor Galvez; Rosalinda Diaz; Leo Bayliss; Juan Fernandez-Ruiz; Aurelio Campos-Romo
Journal:  Eur J Neurosci       Date:  2019-12-18       Impact factor: 3.386

3.  Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis.

Authors:  Sarah J Tabrizi; Rachael I Scahill; Alexandra Durr; Raymund Ac Roos; Blair R Leavitt; Rebecca Jones; G Bernhard Landwehrmeyer; Nick C Fox; Hans Johnson; Stephen L Hicks; Christopher Kennard; David Craufurd; Chris Frost; Douglas R Langbehn; Ralf Reilmann; Julie C Stout
Journal:  Lancet Neurol       Date:  2010-12-02       Impact factor: 44.182

4.  Longitudinal change in regional brain volumes in prodromal Huntington disease.

Authors:  Elizabeth H Aylward; Peggy C Nopoulos; Christopher A Ross; Douglas R Langbehn; Ronald K Pierson; James A Mills; Hans J Johnson; Vincent A Magnotta; Andrew R Juhl; Jane S Paulsen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-09-30       Impact factor: 10.154

5.  Symptom heterogeneity in Huntington's disease correlates with neuronal degeneration in the cerebral cortex.

Authors:  Nasim F Mehrabi; Henry J Waldvogel; Lynette J Tippett; Virginia M Hogg; Beth J Synek; Richard L M Faull
Journal:  Neurobiol Dis       Date:  2016-08-25       Impact factor: 5.996

6.  Regional specificity of brain atrophy in Huntington's disease.

Authors:  G M Halliday; D A McRitchie; V Macdonald; K L Double; R J Trent; E McCusker
Journal:  Exp Neurol       Date:  1998-12       Impact factor: 5.330

7.  Neuropathological classification of Huntington's disease.

Authors:  J P Vonsattel; R H Myers; T J Stevens; R J Ferrante; E D Bird; E P Richardson
Journal:  J Neuropathol Exp Neurol       Date:  1985-11       Impact factor: 3.685

8.  Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.

Authors:  Sarah J Tabrizi; Rachael I Scahill; Gail Owen; Alexandra Durr; Blair R Leavitt; Raymund A Roos; Beth Borowsky; Bernhard Landwehrmeyer; Chris Frost; Hans Johnson; David Craufurd; Ralf Reilmann; Julie C Stout; Douglas R Langbehn
Journal:  Lancet Neurol       Date:  2013-05-09       Impact factor: 44.182

9.  A guide to group effective connectivity analysis, part 2: Second level analysis with PEB.

Authors:  Peter Zeidman; Amirhossein Jafarian; Mohamed L Seghier; Vladimir Litvak; Hayriye Cagnan; Cathy J Price; Karl J Friston
Journal:  Neuroimage       Date:  2019-06-18       Impact factor: 6.556

10.  Targeting Huntingtin Expression in Patients with Huntington's Disease.

Authors:  Sarah J Tabrizi; Blair R Leavitt; G Bernhard Landwehrmeyer; Edward J Wild; Carsten Saft; Roger A Barker; Nick F Blair; David Craufurd; Josef Priller; Hugh Rickards; Anne Rosser; Holly B Kordasiewicz; Christian Czech; Eric E Swayze; Daniel A Norris; Tiffany Baumann; Irene Gerlach; Scott A Schobel; Erika Paz; Anne V Smith; C Frank Bennett; Roger M Lane
Journal:  N Engl J Med       Date:  2019-05-06       Impact factor: 91.245

View more
  5 in total

1.  The progression rate of spinocerebellar ataxia type 3 varies with disease stage.

Authors:  Linliu Peng; Yun Peng; Zhao Chen; Chunrong Wang; Zhe Long; Huirong Peng; Yuting Shi; Lu Shen; Kun Xia; Vanessa B Leotti; Laura Bannach Jardim; Beisha Tang; Rong Qiu; Hong Jiang
Journal:  J Transl Med       Date:  2022-05-14       Impact factor: 8.440

2.  Planning deficits in Huntington's disease: A brain structural correlation by voxel-based morphometry.

Authors:  Jesus Calderon-Villalon; Gabriel Ramirez-Garcia; Juan Fernandez-Ruiz; Fernanda Sangri-Gil; Aurelio Campos-Romo; Victor Galvez
Journal:  PLoS One       Date:  2021-03-24       Impact factor: 3.240

3.  Revealing the Timeline of Structural MRI Changes in Premanifest to Manifest Huntington Disease.

Authors:  Peter A Wijeratne; Sara Garbarino; Sarah Gregory; Eileanoir B Johnson; Rachael I Scahill; Jane S Paulsen; Sarah J Tabrizi; Marco Lorenzi; Daniel C Alexander
Journal:  Neurol Genet       Date:  2021-10-12

Review 4.  Volumetric MRI-Based Biomarkers in Huntington's Disease: An Evidentiary Review.

Authors:  Kirsi M Kinnunen; Adam J Schwarz; Emily C Turner; Dorian Pustina; Emily C Gantman; Mark F Gordon; Richard Joules; Ariana P Mullin; Rachael I Scahill; Nellie Georgiou-Karistianis
Journal:  Front Neurol       Date:  2021-09-21       Impact factor: 4.003

5.  Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.

Authors:  Andrew Feigin; Elizabeth E Evans; Terrence L Fisher; John E Leonard; Ernest S Smith; Alisha Reader; Vikas Mishra; Richard Manber; Kimberly A Walters; Lisa Kowarski; David Oakes; Eric Siemers; Karl D Kieburtz; Maurice Zauderer
Journal:  Nat Med       Date:  2022-08-08       Impact factor: 87.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.